Epcoritamab治疗复发/难治性大B细胞淋巴瘤:关键EPCORE NHL-1试验2年随访
报告EPCORE NHL-1关键研究中复发/难治性大B细胞淋巴瘤患者(N=157)接受epcoritamab单药治疗的中位25.1个月随访的长期疗效与安全性。总缓解率63.1%,完全缓解率40.1%,估计24个月无进展生存率和总生存率分别为27.8%和44.6%。
要点
- 中位随访25.1个月,总缓解率63.1%,完全缓解率40.1%。
- 估计24个月无进展生存率和总生存率分别为27.8%和44.6%。
- 完全缓解者中估计64.2%在24个月时仍维持完全缓解。
核心结论
- Epcoritamab单药治疗复发/难治性大B细胞淋巴瘤具有长期获益,在各亚组中均观察到深度缓解,包括难治性疾病和预期预后差的患者。
研究设计与样本
- 关键EPCORE NHL-1研究长期随访,纳入复发/难治性大B细胞淋巴瘤患者N=157,中位随访25.1个月。
主要发现
- 截至2023年4月21日,总缓解率为63.1%,完全缓解率为40.1%。
- 估计24个月无进展生存率为27.8%,总生存率为44.6%。
- 完全缓解者中估计64.2%在24个月时仍维持完全缓解;完全缓解者估计24个月无进展生存率为65.1%,总生存率为78.2%。
- 119例可评估微小残留病灶(MRD)的患者中,45.4%达到MRD阴性,MRD阴性与更长的无进展生存和总生存相关。
- predefined亚组中完全缓解率基本一致:既往接受嵌合抗原受体(CAR)T细胞治疗者36%,原发难治性疾病者32%,国际预后指数≥3者37%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary results (median follow-up, 10.7 months) from the pivotal EPCORE® NHL-1 study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) demonstrated deep, durable responses with epcoritamab, a CD3xCD20 bispecific antibody, when used as monotherapy. We report long-term efficacy and safety results in patients with LBCL (N = 157; 25.1-month median follow-up). As of April 21, 2023, overall response rate was 63.1% and complete response (CR) rate was 40.1%. Estimated 24-month progression-free survival (PFS) and overall survival (OS) rates were 27.8% and 44.6%, respectively. An estimated 64.2% of complete responders remained in CR at 24 months. Estimated 24-month PFS and OS rates among complete responders were 65.1% and 78.2%, respectively. Of 119 minimal residual disease (MRD)-evaluable patients, 45.4% had MRD negativity, which correlated with longer PFS and OS. CR rates were generally consistent across predefined subgroups: 36% prior chimeric antigen receptor (CAR) T-cell therapy, 32% primary refractory disease, and 37% International Prognostic Index ≥3. The most common treatment-emergent adverse events were cytokine release syndrome (51.0%), pyrexia (24.8%), fatigue (24.2%), and neutropenia (23.6%). These results underscore the long-term benefit of epcoritamab for treating R/R LBCL with deep responses across subgroups, including patients with hard-to-treat disease and expected poor prognosis (ClinicalTrials.gov Registration: NCT03625037).
引用
- Thieblemont C, Karimi YH, Ghesquieres H, et al. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024. PMID: 39322711. doi:10.1038/s41375-024-02410-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。